PEPTIDES AND PEPTIDE DERIVATIVES AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

• US 20100279924A1
• Filed: 06/22/2010
• Published: 11/04/2010
• Est. Priority Date: 02/23/2006
• Status: Abandoned Application

• Current Assignee: Fibrex Medical Research & Development GmbH
• Original Assignee: Fibrex Medical Research & Development GmbH
• Inventors: Henning, Rainer, Reingruber, Sonja, Petzelbauer, Peter
• Application Number:
  US12/820,804
• Publication Number:
  US 20100279924A1
• Time in Patent Office: Days
• US Class Current: 514/1.4
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/75 Fibrinogen
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Therapeutic compositions can include modified peptides which are derived from the chain of the Bbeta(15-42)-fibrin fragment and wherein one or several of the amino acids of the sequence have been substituted by genetically encoded or not genetically encoded amino acids or peptidomimetics. They may exist as free peptides or as C-terminal derivative and/or being linked to a polyethylene glycol (PEG)-polymer, and have anti-inflammatory and/or endothelium stabilizing effects. Esters or amides may for instance be taken into consideration as C-terminal derivatives. Processes for production of the peptides and derivatives thereof are also described.

Claims

1-7. -7. (canceled)

8. A peptide of Formula II:

9. The peptide of claim 8, wherein X₁₇ denotes NR₂R₃, R₂ and R₃ being identical and denoting hydrogen.

10. A pharmaceutical composition, comprising the peptide of claim 8 and a pharmaceutically acceptable additive.

14. A method for preventing or treating Acute Respiratory Distress Syndrome in an individual comprising administering to the individual an effective amount of the peptide of claim 8.

16. A method for preventing or treating Systemic Inflammatory Response Syndrome in an individual comprising administering to the individual an effective amount of the peptide of claim 8.

18. A method for preventing or treating shock in an individual comprising administering to the individual an effective amount of the peptide of claim 8.

20. A method for preventing or treating reperfusion trauma in an individual comprising administering to the individual an effective amount of the peptide of claim 8.

22. A method for preventing or treating Dengue virus in an individual comprising administering to the individual an effective amount of the peptide of claim 8.

24. A method for preventing or treating organ failure in an individual comprising administering to the individual an effective amount of the peptide of claim 8.

11. A peptide of Formula II:

13. A pharmaceutical composition, comprising the peptide of claim 11 and a pharmaceutically acceptable additive.

15. A method for preventing or treating Acute Respiratory Distress Syndrome in an individual comprising administering to the individual an effective amount of the peptide of claim 11.

17. A method for preventing or treating Systemic Inflammatory Response Syndrome in an individual comprising administering to the individual an effective amount of the peptide of claim 11.

19. A method for preventing or treating shock in an individual comprising administering to the individual an effective amount of the peptide of claim 11.

21. A method for preventing or treating reperfusion trauma in an individual comprising administering to the individual an effective amount of the peptide of claim 11.

23. A method for preventing or treating Dengue virus in an individual comprising administering to the individual an effective amount of the peptide of claim 11.

25. A method for preventing or treating organ failure in an individual comprising administering to the individual an effective amount of the peptide of claim 11.

12. The peptide of claim 12, wherein PEG is 20K.